Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JAIME L MAYORAL

Allopathic & Osteopathic Physicians Colon & Rectal Surgery

NPI
1689677916
CMS profile
258659
Location
SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$12,784.84

108 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Honoraria $5,040.00 3
Food and Beverage $4,144.52 93
Travel and Lodging $2,841.58 10
Education $750.00 1
Gift $8.74 1

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
Pacira Pharmaceuticals Incorporated $5,565.62 8
INTUITIVE SURGICAL, INC. $4,222.23 57
TELA Bio, Inc. $2,055.97 18
Medtronic, Inc. $284.58 8
Davol Inc. $281.00 4
Takeda Pharmaceuticals U.S.A., Inc. $128.45 6
Sanara MedTech Inc. $108.08 1
Ethicon US, LLC $66.29 3
Baxter Healthcare $30.04 1
Dilon Technologies, Inc. $24.62 1
CONMED Corporation $17.96 1

Page 3 of 3; records 101–108 of 108 matching records. This page contains 8 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JAIME L MAYORAL

NPI 1689677916 · CMS profile ID 258659

Allopathic & Osteopathic Physicians / Colon & Rectal Surgery

SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–108 of 108 matching records. This page contains 8 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1689677916?year=2024&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JAIME L MAYORAL, NPI 1689677916, CMS profile ID 258659. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–108 of 108 matching records. This page contains 8 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1689677916?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). JAIME L MAYORAL, NPI 1689677916, CMS profile ID 258659. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–108 of 108 matching records. This page contains 8 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1689677916?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
JAIME L MAYORAL, NPI 1689677916, CMS profile ID 258659, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–108 of 108 matching records. This page contains 8 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1689677916?year=2024&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

108 matching records · $12,784.84 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 108 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–108 of 108.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Takeda Pharmaceuticals U.S.A., Inc. $29.4902/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137631755 CMS
INTUITIVE SURGICAL, INC. $374.2001/30/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137242252 CMS
INTUITIVE SURGICAL, INC. $19.0001/30/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137301151 CMS
Ethicon US, LLC $24.2701/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1077649280 CMS
TELA Bio, Inc. $138.4101/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154223568 CMS
Medtronic, Inc. $186.8601/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1119435391 CMS
INTUITIVE SURGICAL, INC. $2.3601/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137161343 CMS
INTUITIVE SURGICAL, INC. $41.6701/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137275621 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $10,141.38 75
PY2020 $7,642.26 58
PY2021 $19,024.14 77
PY2022 $4,592.49 72
PY2023 $2,827.71 55
PY2024 $12,784.84 108
PY2025 $27,192.97 76

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $254,799.56 38
PY2024 Principal investigator $201,857.30 34
PY2023 Principal investigator $231,750.59 68
PY2022 Principal investigator $177,198.13 64
PY2021 Principal investigator $228,731.67 78
PY2020 Principal investigator $372,319.88 95
PY2019 Principal investigator $215,746.82 64

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

38 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 F. Hoffmann-La Roche AG $2,510.00 12/19/2025 Non-covered Recipient Entity
CLINICAL ASSOCIATES IN RESEARCH THERAPEUTICS OF AMERICA LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211586588
Principal investigator 1 F. Hoffmann-La Roche AG $20,036.00 12/11/2025 Non-covered Recipient Entity
CLINICAL ASSOCIATES IN RESEARCH THERAPEUTICS OF AMERICA LLC
CD P3: Double-Blind Induction No dispute reported 06/30/2026 1211586593
Principal investigator 1 F. Hoffmann-La Roche AG $20,036.00 12/11/2025 Non-covered Recipient Entity
CLINICAL ASSOCIATES IN RESEARCH THERAPEUTICS OF AMERICA LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211586596
Principal investigator 1 F. Hoffmann-La Roche AG $1,200.00 12/11/2025 Non-covered Recipient Entity
CLINICAL ASSOCIATES IN RESEARCH THERAPEUTICS OF AMERICA LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211586600
Principal investigator 1 ABBVIE INC. $227.60 12/04/2025 Non-covered Recipient Entity
CLINICAL ASSOCIATES IN RESEARCH
A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis No dispute reported 06/30/2026 1202527466
Principal investigator 1 F. Hoffmann-La Roche AG $2,526.00 12/04/2025 Non-covered Recipient Entity
CLINICAL ASSOCIATES IN RESEARCH THERAPEUTICS OF AMERICA LLC
CD P3: Double-Blind Induction No dispute reported 06/30/2026 1211586604
Principal investigator 1 Genentech, Inc. $5,563.00 11/25/2025 Non-covered Recipient Entity
CLINICAL ASSOCIATES IN RESEARCH THERAPEUTICS OF AMERICA LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211586639
Principal investigator 1 Genentech, Inc. $5,536.00 11/20/2025 Non-covered Recipient Entity
CLINICAL ASSOCIATES IN RESEARCH THERAPEUTICS OF AMERICA LLC
CD P3: Double-Blind Induction No dispute reported 06/30/2026 1211586635
Principal investigator 1 ABBVIE INC. $5,300.00 11/05/2025 Non-covered Recipient Entity
CLINICAL ASSOCIATES IN RESEARCH
A Multicenter Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1202521923
Principal investigator 1 ABBVIE INC. $7,758.66 10/16/2025 Non-covered Recipient Entity
CLINICAL ASSOCIATES IN RESEARCH THERAPEUTICS OF AMERICA LLC
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn Disease No dispute reported 06/30/2026 1202517259
Principal investigator 1 Genentech, Inc. $117.00 10/16/2025 Non-covered Recipient Entity
CLINICAL ASSOCIATES IN RESEARCH THERAPEUTICS OF AMERICA LLC
CD P3: Double-Blind Induction No dispute reported 06/30/2026 1211586624
Principal investigator 1 Genentech, Inc. $19,919.00 10/16/2025 Non-covered Recipient Entity
CLINICAL ASSOCIATES IN RESEARCH THERAPEUTICS OF AMERICA LLC
CD P3: Double-Blind Induction No dispute reported 06/30/2026 1211586630
Principal investigator 1 ABBVIE INC. $234.10 10/09/2025 Non-covered Recipient Entity
CLINICAL ASSOCIATES IN RESEARCH
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 1202513987
Principal investigator 1 ABBVIE INC. $6,525.00 09/30/2025 Non-covered Recipient Entity
CLINICAL ASSOCIATES IN RESEARCH
A Multicenter Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1202512890
Principal investigator 1 F. Hoffmann-La Roche AG $5,606.00 08/07/2025 Non-covered Recipient Entity
CLINICAL ASSOCIATES IN RESEARCH THERAPEUTICS OF AMERICA LLC
CD P3: Double-Blind Induction No dispute reported 06/30/2026 1211586580
Principal investigator 1 ABBVIE INC. $1,677.80 08/05/2025 Non-covered Recipient Entity
CLINICAL ASSOCIATES IN RESEARCH
A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis No dispute reported 06/30/2026 1202501600
Principal investigator 1 ABBVIE INC. $9,025.00 07/22/2025 Non-covered Recipient Entity
CLINICAL ASSOCIATES IN RESEARCH
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) No dispute reported 06/30/2026 1202499104
Principal investigator 1 F. Hoffmann-La Roche AG $40,072.00 07/17/2025 Non-covered Recipient Entity
CLINICAL ASSOCIATES IN RESEARCH THERAPEUTICS OF AMERICA LLC
CD P3: Double-Blind Induction No dispute reported 06/30/2026 1211586583
Principal investigator 1 ABBVIE INC. $703.40 07/15/2025 Non-covered Recipient Entity
CLINICAL ASSOCIATES IN RESEARCH
A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis No dispute reported 06/30/2026 1202498290
Principal investigator 1 ABBVIE INC. $7,261.90 07/02/2025 Non-covered Recipient Entity
CLINICAL ASSOCIATES IN RESEARCH
A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis No dispute reported 06/30/2026 1202495501
Principal investigator 1 ABBVIE INC. $8,286.50 07/02/2025 Non-covered Recipient Entity
CLINICAL ASSOCIATES IN RESEARCH THERAPEUTICS OF AMERICA LLC
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn Disease No dispute reported 06/30/2026 1202496255
Principal investigator 1 ABBVIE INC. $6,463.80 07/02/2025 Non-covered Recipient Entity
CLINICAL ASSOCIATES IN RESEARCH
A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis No dispute reported 06/30/2026 1202496257
Principal investigator 1 ABBVIE INC. $7,953.90 07/02/2025 Non-covered Recipient Entity
CLINICAL ASSOCIATES IN RESEARCH
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 1202496259
Principal investigator 1 ABBVIE INC. $3,506.10 06/17/2025 Non-covered Recipient Entity
CLINICAL ASSOCIATES IN RESEARCH
A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis No dispute reported 06/30/2026 1202491749
Principal investigator 1 F. Hoffmann-La Roche AG $5,569.00 06/12/2025 Non-covered Recipient Entity
CLINICAL ASSOCIATES IN RESEARCH THERAPEUTICS OF AMERICA LLC
CD P3: Double-Blind Induction No dispute reported 06/30/2026 1211586563
Principal investigator 1 F. Hoffmann-La Roche AG $4,429.00 06/12/2025 Non-covered Recipient Entity
CLINICAL ASSOCIATES IN RESEARCH THERAPEUTICS OF AMERICA LLC
CD P3: Double-Blind Induction No dispute reported 06/30/2026 1211586567
Principal investigator 1 F. Hoffmann-La Roche AG $4,016.00 06/12/2025 Non-covered Recipient Entity
CLINICAL ASSOCIATES IN RESEARCH THERAPEUTICS OF AMERICA LLC
CD P3: Double-Blind Induction No dispute reported 06/30/2026 1211586571
Principal investigator 1 F. Hoffmann-La Roche AG $14,175.00 06/12/2025 Non-covered Recipient Entity
CLINICAL ASSOCIATES IN RESEARCH THERAPEUTICS OF AMERICA LLC
CD P3: Double-Blind Induction No dispute reported 06/30/2026 1211586576
Principal investigator 1 ABBVIE INC. $1,205.20 04/03/2025 Non-covered Recipient Entity
CLINICAL ASSOCIATES IN RESEARCH
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 1202470900
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,128.00 04/03/2025 Non-covered Recipient Entity
CLINICAL ASSOCIATES IN RESEARCH
A PROSPECTIVE, MULTI-CENTER REGISTRY FOR PATIENTS WITH SHORT BOWEL SYNDROME No dispute reported 06/30/2026 1223277576
Principal investigator 1 Genentech, Inc. $6,217.00 03/25/2025 Non-covered Recipient Entity
CLINICAL ASSOCIATES IN RESEARCH THERAPEUTICS OF AMERICA LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211586608
Principal investigator 1 Genentech, Inc. $14,175.00 03/25/2025 Non-covered Recipient Entity
CLINICAL ASSOCIATES IN RESEARCH THERAPEUTICS OF AMERICA LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211586612
Principal investigator 1 Genentech, Inc. $5,569.00 03/25/2025 Non-covered Recipient Entity
CLINICAL ASSOCIATES IN RESEARCH THERAPEUTICS OF AMERICA LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211586616
Principal investigator 1 Genentech, Inc. $2,228.00 03/25/2025 Non-covered Recipient Entity
CLINICAL ASSOCIATES IN RESEARCH THERAPEUTICS OF AMERICA LLC
UC P3: Double-Blind Treat Straight Through No dispute reported 06/30/2026 1211586620
Principal investigator 1 ABBVIE INC. $1,762.90 02/05/2025 Non-covered Recipient Entity
CLINICAL ASSOCIATES IN RESEARCH THERAPEUTICS OF AMERICA LLC
M16-000 - A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn Disease No dispute reported 06/30/2026 1202444634
Principal investigator 1 ABBVIE INC. $1,813.60 02/05/2025 Non-covered Recipient Entity
CLINICAL ASSOCIATES IN RESEARCH
M16-066 - A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis No dispute reported 06/30/2026 1202445997
Principal investigator 1 ABBVIE INC. $2,556.00 01/02/2025 Non-covered Recipient Entity
CLINICAL ASSOCIATES IN RESEARCH
M14-430 - A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 1202435947
Principal investigator 1 ABBVIE INC. $1,911.10 01/02/2025 Non-covered Recipient Entity
CLINICAL ASSOCIATES IN RESEARCH
M16-066 - A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis No dispute reported 06/30/2026 1202436077